Emergence and Dynamics of Delusions and Hallucinations Across Stages in Early Psychosis
- PMID: 40020853
- PMCID: PMC12353309
- DOI: 10.1016/j.biopsych.2025.02.891
Emergence and Dynamics of Delusions and Hallucinations Across Stages in Early Psychosis
Abstract
Background: Hallucinations and delusions are often grouped together as positive symptoms of psychosis. However, recent evidence suggests that they may be driven by distinct computational and neural mechanisms. Examining the time course of their emergence may provide insights into the relationship between these underlying mechanisms.
Methods: Participants from the second (N = 719) and third (N = 699) iterations of the North American Prodrome Longitudinal Study (NAPLS 2 and 3) were assessed for timing of clinical high risk for psychosis (CHR-P)-level delusion and hallucination onset. Pre-onset symptom patterns in patients with first-episode psychosis from the Prevention and Early Intervention Program for Psychosis (PEPP-Montréal) (N = 694) were also assessed. Symptom onset was determined at the baseline assessment, and the evolution of symptom patterns was examined over 24 months.
Results: In all 3 samples, participants were more likely to report the onset of attenuated/subthreshold delusions prior to attenuated/subthreshold hallucinations (odds ratios [ORs]: NAPLS 2 = 4.09; NAPLS 3 = 4.14; PEPP, z = 7.01, p < .001) and to present with only attenuated/subthreshold delusions compared with only attenuated/subthreshold hallucinations (ORs: NAPLS 2 = 5.6; NAPLS 3 = 11.11; PEPP = 42.75). The reemergence of attenuated/subthreshold delusions after remission was also more common than reemergence of attenuated/subthreshold hallucinations (ps < .05), which more often resolved first (ps < .001). In both CHR-P samples, ratings of delusional ideation decreased with the onset of attenuated hallucinations (p = .007).
Conclusions: Attenuated/subthreshold delusions tend to emerge before attenuated/subthreshold hallucinations and may play a role in their development. Future work should examine the relationship between the mechanisms that drive these symptoms and its utility for diagnosis and treatment.
Keywords: Clinical high risk; Delusions; First-episode psychosis; Hallucinations; Prodrome.
Copyright © 2025 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Financial Disclosures
DB is a shareholder and founder of Aifred Health, a digital mental health company not involved in the current work. ML reports grants from Roche Canada, grants from Otsuka Lundbeck Alliance, grants and personal fees from Janssen, and personal fees from Otsuka Canada, Lundbeck Canada, and Boehringer Ingelheim outside the submitted work. SW reports that he has received speaking fees from the American Psychiatric Association and from Medscape Features. He has been granted US patent no. 8492418 B2 for a method of treating prodromal schizophrenia with glycine agonists. He is a consultant to and is a partner and owns stock in NW PharmaTech. All other authors report no biomedical financial interests or potential conflicts of interest.
References
-
- Smeets F, Lataster T, Dominguez M-G, Hommes J, Lieb R, Wittchen H-U, van Os J (2012): Evidence that onset of psychosis in the population reflects early hallucinatory experiences that through environmental risks and affective dysregulation become complicated by delusions. Schizophr Bull 38: 531–542. - PMC - PubMed
-
- López-Silva P, Harrow M, Jobe TH, Tufano M, Harrow H, Rosen C (2022): “Are these my thoughts?”: A 20-year prospective study of thought insertion, thought withdrawal, thought broadcasting, and their relationship to auditory verbal hallucinations. Schizophr Res. 10.1016/j.schres.2022.07.005 - DOI - PubMed
-
- Hermans K, van der Steen Y, Kasanova Z, van Winkel R, Reininghaus U, Lataster T, et al. (2020): Temporal dynamics of suspiciousness and hallucinations in clinical high risk and first episode psychosis. Psychiatry Res 290: 113039. - PubMed
Grants and funding
- U01 MH081902/MH/NIMH NIH HHS/United States
- P50 MH080272/MH/NIMH NIH HHS/United States
- U01 MH081988/MH/NIMH NIH HHS/United States
- P50 MH066286/MH/NIMH NIH HHS/United States
- U01 MH076989/MH/NIMH NIH HHS/United States
- WT_/Wellcome Trust/United Kingdom
- U01 MH082022/MH/NIMH NIH HHS/United States
- U01 MH081984/MH/NIMH NIH HHS/United States
- R01 MH129721/MH/NIMH NIH HHS/United States
- R01 MH131768/MH/NIMH NIH HHS/United States
- R21 MH122940/MH/NIMH NIH HHS/United States
- K23 MH115252/MH/NIMH NIH HHS/United States
- U01 MH066160/MH/NIMH NIH HHS/United States
- K24 MH076191/MH/NIMH NIH HHS/United States
- R01 MH060720/MH/NIMH NIH HHS/United States
- U01 MH081928/MH/NIMH NIH HHS/United States
- U01 MH081857/MH/NIMH NIH HHS/United States
- U01 MH082004/MH/NIMH NIH HHS/United States
- U01 MH081944/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources